Anti-TGF beta monoclonal antibody (Lilly)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-TGF beta monoclonal antibody (Lilly)
Drug Alias NameAnti-TGF-beta-1 monoclonal antibody for diabetes抗TGF-β单克隆抗体 - 礼来Anti-TGF β monoclonal antibody
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionImmunomodulatorsTransforming growth factor beta 1 inhibitors
TargetsTransforming growth factor beta 1
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A